Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 1
2010 2
2011 4
2013 2
2014 4
2015 3
2016 2
2017 5
2018 5
2019 6
2020 5
2021 8
2022 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ, Ghione P, Jacobsen E, Ruan J, Schatz JH, Noor S, Myskowski P, Vardhana S, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa A, Dowd J, Obadi O, Pomerantz L, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus D, Kumar P, Dogan A, Hollmann T, Drill E, Rademaker J, Schoder H, Inghirami G, Weinstock DM, Horwitz SM. Moskowitz AJ, et al. Among authors: schatz jh. Blood. 2021 Dec 30;138(26):2828-2837. doi: 10.1182/blood.2021013379. Blood. 2021. PMID: 34653242 Free PMC article. Clinical Trial.
eIF4A inhibition: ready for primetime?
Cunningham TA, Chapman E, Schatz JH. Cunningham TA, et al. Among authors: schatz jh. Oncotarget. 2018 Oct 30;9(85):35515-35516. doi: 10.18632/oncotarget.26268. eCollection 2018 Oct 30. Oncotarget. 2018. PMID: 30473746 Free PMC article. No abstract available.
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.
Major A, Yu J, Shukla N, Che Y, Karrison TG, Treitman R, Kamdar MK, Haverkos BM, Godfrey J, Babcook MA, Voorhees TJ, Carlson S, Gaut D, Oliai C, Romancik JT, Winter AM, Hill BT, Bansal R, Villasboas Bisneto JC, Nizamuddin IA, Karmali R, Fitzgerald LA, Stephens DM, Pophali PA, Trabolsi A, Schatz JH, Hu M, Bachanova V, Slade MJ, Singh N, Ahmed N, McGuirk JP, Bishop MR, Riedell PA, Kline J. Major A, et al. Among authors: schatz jh. Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016. Blood Adv. 2023. PMID: 37026796 Free PMC article.
Progress against follicular lymphoma.
Schatz JH, Oricchio E, Puvvada SD, Wendel HG. Schatz JH, et al. Curr Opin Hematol. 2013 Jul;20(4):320-6. doi: 10.1097/MOH.0b013e3283622ed6. Curr Opin Hematol. 2013. PMID: 23673338 Free PMC article. Review.
Kinase overexpressing cancers responsive to drug withdrawal.
Amin AD, Rajan SS, Schatz JH. Amin AD, et al. Among authors: schatz jh. Aging (Albany NY). 2015 Oct;7(10):752-3. doi: 10.18632/aging.100830. Aging (Albany NY). 2015. PMID: 26525633 Free PMC article. No abstract available.
48 results